Impact of immunosuppressive regimen on ICU acquired pneumonia in critically ill COVID-19
Description
CONCLUSIONS: In critically ill COVID-19, HDMB significantly increases the risk of IAP whereas DXM alone, nor in combination with tocilizumab, did not.
